Literature DB >> 16907922

Assessment of in vitro immunity to Mycobacterium tuberculosis in a human peripheral blood infection model using a luciferase reporter construct of M. tuberculosis H37Rv.

R Al-Attiyah1, A El-Shazly, A S Mustafa.   

Abstract

Protective immune responses to tuberculosis in man are primarily cell-mediated and require the interaction of specific T cells, cytokines and activated macrophages. In the present study, Mycobacterium tuberculosis H37Rv labelled with luciferase reporter enzyme was used to analyse the anti-mycobacterial immunity in man using an in vitro whole blood infection model. Peripheral blood samples obtained from M. bovis bacille Calmette-Guérin (BCG)-vaccinated tuberculin-positive healthy volunteers (n = 23) were cultured with M. tuberculosis H37Rv reporter strain. The growth of bacteria in the whole blood cultures was monitored after 48 and 96 h of infection. The results showed that the growth of M. tuberculosis was significantly inhibited after 96 h (P < 0.029) of culture. Among the cytokines studied, interleukin (IL)-10 and IL-12 were not detected at all, whereas low levels of interferon (IFN)-gamma after 96 h (0.4 IU/ml) and tumour necrosis factor (TNF)-alpha after 48 (135 pg/ml) and 96 h (47 pg/ml) of culture were detected in the supernatants of whole blood infected with M. tuberculosis. The magnitude of bacterial growth correlated directly with the concentration of TNF-alpha detected after 48 h (r = 0.722) and 96 h (r = 0.747) of culture (P <or= 0.0001 and P <or= 0.0001, respectively). However, the addition of monoclonal antibodies specific to TNF-alpha and IFN-gamma to the blood cultures did not alter mycobacterial growth indicating the role of other mechanisms/factors in restricting the growth of M. tuberculosis in whole blood cultures.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16907922      PMCID: PMC1809703          DOI: 10.1111/j.1365-2249.2006.03133.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  Effect of stimulation of human macrophages on intracellular survival of Mycobacterium bovis Bacillus Calmette-Guerin. Evaluation with a mycobacterial reporter strain.

Authors:  M Bonay; F Bouchonnet; V Pelicic; B Lagier; M Grandsaigne; D Lecossier; A Grodet; M Vokurka; B Gicquel; A J Hance
Journal:  Am J Respir Crit Care Med       Date:  1999-05       Impact factor: 21.405

2.  Induction of in vitro human macrophage anti-Mycobacterium tuberculosis activity: requirement for IFN-gamma and primed lymphocytes.

Authors:  M G Bonecini-Almeida; S Chitale; I Boutsikakis; J Geng; H Doo; S He; J L Ho
Journal:  J Immunol       Date:  1998-05-01       Impact factor: 5.422

3.  Lymphocyte-dependent inhibition of growth of virulent Mycobacterium tuberculosis H37Rv within human monocytes: requirement for CD4+ T cells in purified protein derivative-positive, but not in purified protein derivative-negative subjects.

Authors:  R F Silver; Q Li; W H Boom; J J Ellner
Journal:  J Immunol       Date:  1998-03-01       Impact factor: 5.422

4.  Growth of virulent and avirulent Mycobacterium tuberculosis strains in human macrophages.

Authors:  M Zhang; J Gong; Y Lin; P F Barnes
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

5.  Morphometric analysis of Th(1) and Th(2) cytokine expression in human pulmonary tuberculosis.

Authors:  Xiyuan Bai; Sarah E Wilson; Kathryn Chmura; Nicole E Feldman; Edward D Chan
Journal:  Tuberculosis (Edinb)       Date:  2004       Impact factor: 3.131

6.  Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project.

Authors:  C Dye; S Scheele; P Dolin; V Pathania; M C Raviglione
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

7.  CD4(+) T cell and natural killer cell-dependent killing of Mycobacterium tuberculosis by human monocytes.

Authors:  T Yoneda; J J Ellner
Journal:  Am J Respir Crit Care Med       Date:  1998-08       Impact factor: 21.405

8.  Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice.

Authors:  M J Hickey; T M Arain; R M Shawar; D J Humble; M H Langhorne; J N Morgenroth; C K Stover
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

9.  An antimicrobial activity of cytolytic T cells mediated by granulysin.

Authors:  S Stenger; D A Hanson; R Teitelbaum; P Dewan; K R Niazi; C J Froelich; T Ganz; S Thoma-Uszynski; A Melián; C Bogdan; S A Porcelli; B R Bloom; A M Krensky; R L Modlin
Journal:  Science       Date:  1998-10-02       Impact factor: 47.728

10.  Assessment of immunity to mycobacterial infection with luciferase reporter constructs.

Authors:  V A Snewin; M P Gares; P O Gaora; Z Hasan; I N Brown; D B Young
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

View more
  4 in total

1.  Comparative evaluation of MPT83 (Rv2873) for T helper-1 cell reactivity and identification of HLA-promiscuous peptides in Mycobacterium bovis BCG-vaccinated healthy subjects.

Authors:  Abu S Mustafa
Journal:  Clin Vaccine Immunol       Date:  2011-08-18

2.  Optimisation of bioluminescent reporters for use with mycobacteria.

Authors:  Nuria Andreu; Andrea Zelmer; Taryn Fletcher; Paul T Elkington; Theresa H Ward; Jorge Ripoll; Tanya Parish; Gregory J Bancroft; Ulrich Schaible; Brian D Robertson; Siouxsie Wiles
Journal:  PLoS One       Date:  2010-05-24       Impact factor: 3.240

3.  Efficient testing of large pools of Mycobacterium tuberculosis RD1 peptides and identification of major antigens and immunodominant peptides recognized by human Th1 cells.

Authors:  Abu S Mustafa; Raja'a Al-Attiyah; Sumaila N M Hanif; Fatema A Shaban
Journal:  Clin Vaccine Immunol       Date:  2008-04-09

4.  A novel mycobacterial In Vitro infection assay identifies differences of induced macrophage apoptosis between CD4+ and CD8+ T cells.

Authors:  Vanesa Nkwouano; Sven Witkowski; Nidja Rehberg; Rainer Kalscheuer; Norman Nausch; Ertan Mayatepek; Marc Jacobsen
Journal:  PLoS One       Date:  2017-02-15       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.